Corporate proxy campaigns typically don’t grab headlines, but an upcoming shareholder vote at a biotech firm could have major implications for the future of research on Alzheimer’s disease and dementia.
The genesis of the proxy fight revolves around the prospects of fosgonimention, which experts view as a potential game-changing treatment for Alzheimer’s disease, Parkinson’s disease and other dementia. As an estimated 35 million people are diagnosed with Alzheimer’s worldwide and 900,000 are diagnosed annually in the U.S., Athira is running a clinical trial that could drastically improve the quality of life for families and seniors across the globe.
Read Full Article »